We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > FAP

News List

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) americanpharmaceuticalreview
April 07, 2021
Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with ...
Novartis signs deal with iTheranostics to develop, commercialise compounds targeting FAP expresspharma
March 31, 2021
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialise therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74.
EU filing for CPP's familial adenomatous polyposis drug pharmatimes
June 22, 2020
US private biotech Cancer Prevention Pharmaceuticals has filed a marketing application in Europe for CPP-1X/sul, a preventative treatment for patients with familial adenomatous polyposis (FAP).